US20030096752A1 - Aprotinin variants having improved properties - Google Patents

Aprotinin variants having improved properties Download PDF

Info

Publication number
US20030096752A1
US20030096752A1 US10/252,967 US25296702A US2003096752A1 US 20030096752 A1 US20030096752 A1 US 20030096752A1 US 25296702 A US25296702 A US 25296702A US 2003096752 A1 US2003096752 A1 US 2003096752A1
Authority
US
United States
Prior art keywords
aprotinin
arg15
asn41
glu53
thr26
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/252,967
Inventor
Werner Schroder
Soren Bjorn
Kjeld Norris
Viggo Diness
Leif Norkskov-Lauritsen
Niels Christensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/252,967 priority Critical patent/US20030096752A1/en
Publication of US20030096752A1 publication Critical patent/US20030096752A1/en
Assigned to SCHRODER, WERNER reassignment SCHRODER, WERNER ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAYER AKTIENGESELLSCHAFT
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to aprotinin variants having improved enzyme-inhibitory, immunological and pharmacokinetic properties and their preparation.
  • Aprotinin which is also called bovine pancreatic trypsin inhibitor (BPTI) belongs to the family of serine protease inhibitors of the Kunitz type.
  • the spectrum of the inhibitable serine proteases includes, for example, trypsin, chymotrypsin, plasmin and plasma kallikrein (W. Gebhard, H. Tschesche and H. Fritz, Proteinase Inhibitors, Barrett and Salvesen (eds.), Elsevier Science Publ. BV 375-387, 1986).
  • Aprotinin consists of 58 amino acids.
  • the three-dimensional structure of the protein was elucidated with the aid of X-ray structural analysis and NMR spectroscopy (Wlodawer et al., J. Mol. Biol. 198 (3), 469-480, 1987; Wagner et al., J. Mol. Biol. 196 (1), 227-231, 1987; Berndt et al., Biochemistry 32 (17), 4564-4570, 1993).
  • Trasylol® natural aprotinin was originally employed for the treatment of pancreatitis.
  • Trasylol® is today used in cardiac surgery, since clinical studies have shown that treatment with aprotinin significantly decreases the need for transfusion in operations of this type and leads to the reduction of post-operative bleeding (D. Royston, J. Cardiothorac. Vase. Anesth. 6; 76-100, 1992).
  • inhibitory properties of aprotinin and of the variants produced by replacement in position 15 is also determined by further amino acid residues in the contact region between the target protease to be inhibited and the inhibitor molecule. These especially include the additional amino acid residues in positions 14, 16, 17, 18, 19, 34, 38 and 39. Aprotinin variants having improved properties due to replacement of one or more of these amino acid residues in the area of the contact region were described, inter alia, in the following patent applications by way of example: WO 89/01968, WO 89/10374, EP 0 307 592, EP 683 229.
  • N-terminal end of the inhibitor molecule For reasons of better industrial preparability, it is convenient in certain cases to carry out a modification to the N-terminal end of the inhibitor molecule. Such modifications can be N-terminal contractions or extensions or deletions of one or more amino acids. N-terminally modified aprotinin variants were described in EP 419 878.
  • the aprotinin variants according to the invention are not restricted, however, to the examples named in FIG. 1.
  • the aprotinin variants according to the invention also include variants with the N-terminal extension Ala(2)-Gln(1), with the natural amino acid residue proline in position 2, with the replacement of other amino acids which carry a positive charge by neutral or negatively charged amino acid residues, or with the replacement of other neutral amino acids by negatively charged amino acid residues.
  • the choice of the replacements of amino acid residues here follows the principle of producing a substance which at physiological pH has a reduced positive net charge, preferably in the range from +2 to ⁇ 2.
  • the changes in the amino acid sequence mentioned, including the N-terminal extension or contractions or deletions can be utilized in any desired combination with one another.
  • the aprotinin variants according to the invention thus include all compounds which contain a combination of the abovementioned features and at physiological pH have a reduced positive net charge.
  • the variants according to the invention induce a lower release of histamine from blood cells in comparison with aprotinin.
  • the new variants furthermore show a distinctly lower renal accumulation in comparison with aprotinin.
  • the enzyme-kinetic inhibition constants (K i values) have been surprisingly improved compared with earlier variants of the molecule, in spite of the large number of changes in the body of the molecule.
  • the present invention thus relates to aprotinin variants having a net charge of +3 to ⁇ 3 at pH 7 and with the amino acids Arg 15 or Arg 15-Ala 17.
  • Preferred variants are those having a net charge of +2 to ⁇ 2, particularly preferably those having a charge of +1 to ⁇ 1.
  • aprotinin variants are suitable for the inhibition of plasma kallikrein, tissue kallikrein and plasmin.
  • these aprotinin variants can have a modified N-terminal sequence.
  • Preferred aprotinin variants are those from the group consisting of DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin, DesPro2-Ser10-Arg15-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin, DesPro2-Ser10-Arg15-Ser17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin, DesPro2-Ser10-Arg15-Ala17-Thr26-Glu31-Asn41-Glu53-aprotinin and DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Asn41-Glu53-aprotinin.
  • aprotinin variants can also carry the amino acid proline in position 2.
  • the invention also relates to medicaments comprising one or more of these aprotinin variants.
  • novel proteinase inhibitors described are suitable for the treatment of disease states in which—also as a result of relatively complex surgical methods such as, for example, in cardiac surgery or in alloarthroplastic joint replacement in transplantation medicine—activation of the plasmatic enzyme systems occurs due to extensive or intensive foreign surface contact of the blood.
  • the inhibitors reduce the blood loss in operations which are associated with an increased risk of bleeding (e.g. heart operations, bone and joint surgery). They are suitable for therapy in the case of shock, polytrauma and cranial and brain trauma, sepsis, disseminated intravasal coagulopathy (DIC), multi-organ failure, inflammatory disorders with involvement of the kallikrein system such as rheumatic joint disorders and asthma. They prevent invasive tumour growth and metastasis by inhibition of plasmin. They are also suitable for pain and oedema therapy due to inhibition of bradykinin synthesis, and for the treatment of strokes. They are also suitable for dialysis therapy and certificial organs to prevent inflammatory disorders, coagulation and increased risk of bleeding.
  • DIC disseminated intravasal coagulopathy
  • the genetic engineering information for the synthesis of the aprotinin variants considered in each case is introduced into a suitable microbial expression organism.
  • the recombinant microorganism is fermented; by choice of suitable conditions, the heterologous hereditary information is expressed.
  • the expressed aprotinin variant is subsequently obtained from the culture broth.
  • Suitable host organisms for the production of the aprotinin variants according to the invention can be bacteria, yeasts or fungi. Expression can be effected intracellularly or, using suitable secretion systems, extracellularly.
  • the aprotinin variants can be correctly processed or fused to peptides or proteins.
  • the enzymes used were obtained from Boehringer Mannheim and GIBCO/BRL and employed according to the instructions of the manufacturers.
  • Routine cloning tasks such as, for example, the isolation of plasmid DNA from E. coli (so-called miniprep) and the transformation of E. coli with plasmid DNA were carried out according to Sambrook et al. (Molecular Cloning Cold Spring Harbor, 1989).
  • the host organism employed for transformations was the E. coli strain DH5 ⁇ (GIBCO/BRL).
  • Qiagen tips Qiagen
  • the extraction of DNA fragments from agarose gels was carried out with the aid of Jetsorb according to the details of the manufacturer (Genomed).
  • Oligonucleotides for “site-directed mutagenesis” experiments and primers for PCR and sequencing reactions were prepared using the “380 A DNA synthesizer” from Applied Biosystems.
  • the mutagenesis experiments were carried out according to a process of Deng and Nickoloff (Deng et al., Anal. Biochem. 200, 81-88, 1992) using a kit from Pharmacia Biotech (“Unique Site Elimination Mutagenesis”). All vector constructs and mutagenesis experiments were confirmed by Taq cycle DNA sequencing using fluorescence-labelled terminators on an “ABI 373 A sequencer” (Applied Biosystems).
  • Yeast cells e.g. the strain JC34. 4D (MAT ⁇ , ura3-52, suc2), were cultured in 10 ml of YEPD (2% glucose; 2% peptone; 1% Difco yeast extract) and harvested at an O.D. 600 nm of 0.16 to 0.8. The cells were washed with 5 ml of solution A (1 M sorbitol; 10 mM bicine pH 8.35; 3% ethylene glycol), resuspended in 0.2 ml of solution A and stored at ⁇ 70° C.
  • YEPD 2% glucose; 2% peptone; 1% Difco yeast extract
  • Plasmid DNA (5 ⁇ g) and carrier DNA (50 ⁇ g from herring sperm) were added to the frozen cells. The cells were then thawed by shaking for 5 min at 37° C. After addition of 1.5 ml of solution B (40% PEG 1000, 200 mM bicine pH 8.35), the cells were incubated at 30° C. for 60 min, washed with 1.5 ml of solution C (0.15M NaCl; 10 mM bicine pH 8.35) and resuspended in 100 ⁇ l. Plating-out was carried out on a selective medium with 2% agar. Transformants were obtained after an incubation of 3 days at 30° C.
  • solution B 50% PEG 1000, 200 mM bicine pH 8.35
  • SD2 medium Bacto Yeast Nitrogen Base 6.7 g/l Glucose* 20 g/l KH 2 PO 4 6.7 g/l pH 6.0 2.
  • SC5 medium Glucose* 20 g/l Difco yeast extract 20 g/l KH 2 PO 4 6.7 g/l (NH 4 ) 2 SO 4 2.0 g/l MgSO 4 ⁇ 7 H 2 O 1.0 g/l Trace element solution SL4 1.0 ml/l pH 6.0 Trace element solution SL4: Titriplex III 5 g/l FeSO 4 ⁇ 7 H 2 O 2 g/l ZnSO 4 ⁇ 7 H 2 O 0.1 g/l MnCl 2 ⁇ 4 H 2 O 0.03 g/l H 3 BO 3 0.3 g/l CoCl 2 ⁇ 6 H 2 O 0.2 g/l CuCl 2 ⁇ 2 H 2 O 0.01 g/l NiCl 2 ⁇ 6 H 2
  • Fermenter medium Glucose* 2.0 g/l Soya peptone 25.0 g/l KH 2 PO 4 1.4 g/l MgSO 4 ⁇ 7 H 2 O 1.0 g/l Thiamine chloride 5.1 mg/l Inositol 20 mg/l Trace element solution 3 ml/l Vitamin solution 3 ml/l (NH 4 ) 2 SO 4 3.8 g/l pH 5.5 Feed solution: Glucose* 530 g/l (NH 4 ) 2 SO 4 5.0 g/l KH 2 PO 4 2.9 g/l MgSO 4 ⁇ 7 H 2 O 3.8 g/l Thiamine chloride 13 mg/l Inositol 70 mg/l Trace element solution 6.8 ml/l Vitamin solution 6.8 ml/l Trace element solution: FeCl 3 ⁇ 6 H 2 O 13.5 g/l ZnCl 2 ⁇ 4 H 2 O 2.0 g/l H 3 BO 3 0.5 g/l CoCl 2 ⁇
  • Vitamin solution 100 ml/l Vitamin solution: Riboflavin 0.42 g/l Ca pantothenate 5.9 g/l Nicotinic acid 6.1 g/l Pyridoxine hydrochloride 1.7 g/l Biotin 0.06 g/l Folic acid 0.04 g/l
  • Head space pressure 200 mbar
  • the pH was lowered to 3.0 by addition of 50% (w/v) citric acid and the fermenter was heated at 70° C. for 10 min. The cells were then separated off by centrifugation at 7,500 ⁇ g and the supernatant was handed over for protein purification.
  • sequence analyses were carried out using a protein sequencer model 473A from Applied Biosystems (Forster City, USA). The standard sequencing programme was used. The sequencer, the various sequencing programmes and the PTH detection system are described in detail in the operating handbook (User's manual protein sequencing system model 473 A) (1989) Applied Biosystems Forster City, Calif. 94404, USA).
  • HPLC analyses were carried out using an HP 1090 HPLC system from Hewlett Packard (D-Waldbronn).
  • An RP-18 HPLC column 250 mm ⁇ 4.6 mm, 5 ⁇ material, 300 Angström pore diameter) from Backerbond (D-Gro ⁇ Gerau) was used for the separation.
  • the capillary electrophoresis Model 270 A-HT was from Applied Biosystems (Forster City, Calif. 94404, USA). As a rule, the samples were injected hydrodynamically over various time intervals.
  • the capillary column used 50 ⁇ m ⁇ 72 cm was from Applied Biosystems.
  • amino acid analyses were carried out with an amino acid analyser LC 3000 from Eppendorf Biotronik (D-Maintal). A slightly modified standard separation programme from Biotronik was used. The separation programme and the function of the analyser are described in detail in the apparatus handbook.
  • the molecular weights were determined with a MALDI I system from Kratos/Shimadzu (D-Duisburg).
  • the SDS electrophoreses were carried out with an electrophoresis system from Pharmacia (D-Freiburg).
  • Enzymes and substrates were from Calbiochem (D-Bad Soden). All other chemicals and reagents were from Merck (D-Darmstadt) or Sigma (D-Deisenhofen). 96-well plates were obtained from Greiner.
  • the polyclonal rabbit anti-aprotinin antibodies were raised in rabbits by immunization with aprotinin.
  • the human polyclonal anti-aprotinin antibodies come from patients who were treated with aprotinin.
  • the SDS gel electrophoresis was carried out according to the conditions of Laemmli. 10 ⁇ g of the protease inhibitor were analysed using a 10-20% strength SDS gel and visualized by means of silver staining (Merril et al.).
  • protease inhibitor 1 ⁇ g was analysed using the MALDI technique.
  • the matrix used was sinapic acid.
  • the standard proteins for mass calibration were bovine insulin, cytochrome C and melittin.
  • the protein content is determined according to the BCA method.
  • Cu 2+ ions are reacted by means of the proteins present to give Cu 1+ ions which form a complex with bicinchoninic acid, which absorbs at 560 nm.
  • the lyophilized protein is brought to equilibrium moisture content and dissolved in 0.9% NaCl solution at a concentration of 1 mg/ml.
  • a dilution series is prepared. 1000 ⁇ l of BCA test reagent (Pierce) are added to 50 ⁇ l of sample solution, and the test tube is firmly closed with a stopper and incubated at 60° C. for exactly 30 minutes. After cooling the samples in an ice bath for 5 minutes, measurement is carried out at a temperature of 25° C. and a wavelength of 560 nm.
  • the activity is determined according to a modified F.I.P. trypsin inhibition test.
  • Bay y 19-8757 inhibits the trypsin-catalysed hydrolysis of N ⁇ -benzoyl-L-arginine ethyl ester (BAEE).
  • the carboxyl groups liberated in the reaction are determined by the alkali titration.
  • the trypsin residual activity is a measure of the inhibitory activity of the active compound.
  • the lyophilized protein is brought to equilibrium moisture content, dissolved in 0.9% NaCl solution at a concentration of 1 mg/ml and a dilution series is prepared.
  • 2 ml of buffer (15 mM borate buffer, pH 8.0 containing 200 mM CaCi 2 ) and 0.8 ml of trypsin solution (2 mg/ml) are added to 1 ml of sample solution and the mixture is incubated at 25° C. for 5 minutes.
  • 0.2 ml of BAEE solution (6.8 mg/ml) is then added and the KOH consumption is measured over the course of 5 minutes.
  • the substrate reaction was carried out with TMB substrate+peroxidase solution (1+1; 100 ⁇ l per well). The reaction was stopped after 10 min using 100 ⁇ l/well of 2 M phosphoric acid and the absorption was measured at 450 nm (reference 570 nm).
  • the starting material used for the preparation of the DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin gene was a DesPro2-Arg15-Ala17 gene, which was cloned into the vector pUC 18 by means of the restriction enzymes HindIII and BamHI.
  • the resulting vector (pEM6.6.L) was subjected to a double strand mutagenesis reaction according to the U.S.E. process (Pharmacia Biotech) with the mutagenesis primer A and the Scal/Mlul U.S.E. selection primer.
  • the mutagenesis primer A had the following sequence:
  • the further replacements in the 5′ area of the gene (Ser10-Asp24-Thr26-Glu31) were produced with the aid of the PCR technique using the primer B and the ‘reverse 24-mer M13’ primer starting from pEM31.8.L plasmid DNA.
  • the primer B had the following sequence:
  • the PCR mixture contained 20 ng of pEM31.8.L plasmid DNA, 20 ⁇ mol of ‘reverse 24-mer M13’ primer, 60 pmol of primer B, 200 ⁇ M of dNTPs, 1 ⁇ PCR reaction buffer II (Perkin Elmer), 4 mM MgCl 2 and 2.5 U of Taq DNA polymerase (Perkin Elmer) in a total volume of 100 ⁇ l.
  • the ‘cycle’ conditions were: 3 min at 94° C., 30 cycles of, in each case, 1 min at 94° C., 1 min at 55° C. and 1 min at 72° C. and a subsequent 5 min incubation at 72° C.
  • the PCR mixture was diluted 1:5 and ligated with the vector pCRII (Invitrogen). Using the ligation mixture, E. coli DH5 ⁇ cells were transformed. Positive clones were identified after a restriction digestion with the enzymes XhoI and BamHI and several clones were sequenced. The clone pES9.10.L contained the desired sequence and was employed for the further studies.
  • An E. coli /yeast shuttle vector (e.g. pA202) was used for the construction of a yeast secretion vector in which the DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin sequence is linked to the yeast alpha-factor pre-pro sequence.
  • the vector pA202 carries an ampicillin resistance gene (bla) and a URA3 gene as selectable marker genes for E. coli and yeast. Further essential elements of the vector are the Co1 E1 and the 2 ⁇ origin of replication (ori). The REP3 locus is also situated in this region.
  • a 1200 bp EcoRI HindIII fragment carries the MF ⁇ 1 promoter and the N-terminal pre-pro sequence of the yeast alpha-factor precursor protein (Kurjan and Herskowitz, Cell 30, 933 943, 1982).
  • the vector carries a BamHI-saII fragment of the yeast URA3 gene, which functions in this position as a termination signal for transcription (Yarger et al., Mol. Cell. Biol. 6, 1095-1101, 1986).
  • a 180 bp DNA fragment was excised from the vector pES9.10.L with Xhol and BamHI, purified by means of agarose gel electrophoresis and cloned into the vector pA202 which was also cleaved with Xhol and BamHI and dephosphorylated.
  • the DesPro2-Arg15-aprotinin in the vector pA202 is replaced by the DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin.
  • Yeast cells (JC34.4D) were cloned using the vector pES13.10.L resulting from this cloning.
  • E. coli /yeast shuttle vectors with different promoters such as, for example, the constitutive GAPDH or the inducible GAL 10 promoter, can be prepared in a similar manner and also lead to the secretion of DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin.
  • shuttle vectors with other yeast replication origins, such as, for example, the segment (ars) which autonomically replicates chromosomally.
  • suitable selectable marker genes are those genes which help an auxotrophic yeast mutant to prototrophy, such as, for example, the LEU2, HIS3 or TRP1 genes. Additionally, genes can of course also be employed whose products impart resistance to various antibiotics, such as, for example, the aminoglycoside G418.
  • yeasts such as, for example, the methylotrophic yeasts Pichia pastoris or Hansenula polymorpha , are also able, after transformation with suitable vectors, to produce DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin.
  • the MF ⁇ 1 promoter with the ⁇ -factor pre-sequence and the 5′ end of the aprotinin gene was first amplified by means of PCR and cloned.
  • the primers used had the following sequence:
  • the PCR mixture contained 200 ng of pA202 plasmid DNA, 0.2 ⁇ M primer C, 0.2 ⁇ M primer D, 200 ⁇ M dNTPs, 1 ⁇ PCR reaction buffer 11 (Stratagene, Opti-PrimeTM) and 2.5 U of Taq DNA polymerase (Perkin Elmer) in a total volume of 50 ⁇ l.
  • the ‘cycle’ conditions were: 1 min at 94° C., 30 cycles with, in each case, 1 min at 94° C., 1 min at 50° C. and 2 min at 72° C. and a subsequent 5 min incubation at 72° C.
  • the PCR mixture was diluted 1:5 and ligated with the vector pCRII (Invitrogen).
  • E. coli DH5 ⁇ cells were transformed. Positive clones were identified after a restriction digestion with the enzyme EcoRI and several clones were sequenced. The clone pIU20.11.L was employed for the further studies.
  • the E. coli /yeast shuttle vector pYES2 (Invitrogen) was used for the construction of a yeast secretion vector in which the Ser10-Arg15-Ala17-Asp24-Thr26-Glu311-Asn41-Glu53-aprotinin sequence is linked directly to the yeast alpha-factor pre-sequence.
  • the vector pYES2 was first cleaved with the restriction enzymes SspI and BamHI, dephosphorylated and gel-purified.
  • the GAL1 promoter present on the vector pYES2 and the f1 ori are removed in this way.
  • the expression vector pIU28.11.L no longer contains an ⁇ -factor pro-sequence, so that the processing of the Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin takes place exclusively by means of the signal peptidase and is independent of the cleavage by the KexII protease.
  • a Saccharomyces cerevisiae expression strain was fermented as described above.
  • the cells are separated off by centrifugation and the supernatant which remains is filtered in order to remove remaining cells.
  • the cell-free supernatant is adjusted to pH 3 by addition of concentrated citric acid.
  • the solution must be suitably diluted with purified water in order to establish a conductivity of less than 8 mS/cm.
  • the solution is applied to a cation exchanger column, which has previously been equilibrated with an acid buffer. Unbound material is removed by copious washing with starting buffer.
  • the product is eluted with the aid of a salt gradient.
  • the fractions obtained are investigated further for their product content with the aid of reverse-phase high-pressure liquid chromatography (RP-HPLC) and a biological activity test which determines the protease inhibition. Fractions which contain the product are combined and applied directly to a preparative RP-HPLC column.
  • RP-HPLC reverse-phase high-pressure liquid chromatography
  • the column was previously equilibrated with an acidic buffer. Unbound protein is removed by washing the column with starting buffer. The product is eluted with the aid of an organic solvent gradient. The fractions are again investigated further for their product content as already described above and those fractions which contain product are combined. Depending on the purity of the product achieved, it may possibly be necessary to purify the combined fractions on a second RP-HPLC column. The conditions are essentially the same as those already described.
  • the product solution obtained is diluted with water for injection purposes and dispensed in suitable portions and freeze-dried.
  • the column had previously been equilibrated with 50 nM citrate-NaOH buffer, pH 3. Unbound protein was removed by intensive washing with the same buffer. The product was then eluted with the aid of a salt gradient (1 M NaCl). The fractions obtained were investigated for their product content with the aid of reverse-phase high-pressure liquid chromatography (RP-HPLC, C4) and by testing of the protease inhibition activity. Those fractions which contain the desired product were combined.
  • RP-HPLC, C4 reverse-phase high-pressure liquid chromatography
  • the product-containing solution was diluted with water for injection purposes and applied to the second RP-HPLC column (Vydac C8, Vydac, USA), which had previously been equilibrated with 0.1% trifluoroacetic acid/water. Unbound protein was removed by intensive washing with the same buffer. The product was eluted with the aid of a linear acetonitrile gradient (0-70%). The fractions obtained were again investigated for the product content using the methods described above and those which contained product were combined.
  • the enzyme/inhibitor solution was preincubated at room temperature for 4 hours. 180 ⁇ l of each solution was then added to the well of a microtitre plate and mixed with 20 ⁇ l of substrate solution. The change in the absorption was measured at 405 nm for 10 min. The rate of the enzyme reactions was determined and the K i value was calculated from this according to the method of Bieth (Biochemical Medicine 32: 387-97 (1984)).
  • Substrate stock solution 0.1M in DMSO
  • Substrate solution 1 ⁇ 10 ⁇ 3 M S-2302 in assay buffer
  • Assay buffer 0.05M tris-(hydroxymethyl)-aminomethane, 0.1M NaCl, 0.05% Tween 20; pH 8.2; 1 ml of benzyl alcohol/l.
  • the kinetic constants of the complexation with the enzymes plasmin factor XIa, bovine trypsin and chymotrypsin were determined by the same procedure.
  • the substrates were Chromozym PL for plasmin, HD-Pro-Phe-Arg-pNA for factor XI, S-2444 for trypsin and Suc-Phe-Leu-Phe-pNA for chymotrypsin.
  • the protease inhibitor DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin was prepared by secretion by means of a yeast organism modified by genetic engineering. It was purified to homogeneity from the yeast supernatant by various chromatographic processes. The identity of the inhibitor with the cloned sequence is shown by the following protein analytical investigations.
  • the protease inhibitor was completely sequenced over 57 steps. The following list shows the protein sequence determined, which is identical to the cloned sequence. 1 Arg-Asp-Phe-Cys-Leu-Glu-Pro-Pro-Ser-Thr-Gly-Pro- Cys-Arg-Ala-Ala-IIe-IIe-Arg-Tyr- 21 Phe-Tyr-Asp-Ala-Thr-Ala-Gly-Leu-Cys-Glu-Thr-Phe- Val-Tyr-Gly-Gly-Cys-Arg-Ala- 40 Asn-Arg-Asn-Asn-Phe-Lys-Ser-Ala-Glu-Asp-Cys-Met- Glu-Thr-Cys-Gly-Gly-Ala
  • Capillary electrophoresis allows the separation of peptides and proteins on the basis of their charge in an electrical field.
  • the quality of the separation in this case depends on the buffer, the pH, the temperature and the additives used.
  • the capillaries employed are so-called “fused silica” columns having an internal diameter of 50-100 ⁇ m. DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin was separated on a “fused silica” column in an electrical field.
  • the electropherogram shows a narrow peak.
  • the molecular weight of DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin was determined to be 6223 daltons using the MALDI technique. In this case, the molecular weight determined is in good agreement with the theoretical value of 6215 daltons within the bounds of the accuracy of the measuring method. Sinapic acid was employed as a matrix.
  • protease inhibitors prepared by recombinant methods were investigated further for their cross-reactivity using polyclonal rabbits or human anti-aprotinin antibodies. It was found that the various protease inhibitor variants only show a very weak interaction with the aprotinin antisera.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

The present invention relates to aprotinin variants having improved enzyme-inhibitory, immunological and pharmacokinetic properties and their preparation.

Description

  • The present invention relates to aprotinin variants having improved enzyme-inhibitory, immunological and pharmacokinetic properties and their preparation. [0001]
  • Aprotinin, which is also called bovine pancreatic trypsin inhibitor (BPTI), belongs to the family of serine protease inhibitors of the Kunitz type. The spectrum of the inhibitable serine proteases includes, for example, trypsin, chymotrypsin, plasmin and plasma kallikrein (W. Gebhard, H. Tschesche and H. Fritz, Proteinase Inhibitors, Barrett and Salvesen (eds.), Elsevier Science Publ. BV 375-387, 1986). [0002]
  • Aprotinin consists of 58 amino acids. The three-dimensional structure of the protein was elucidated with the aid of X-ray structural analysis and NMR spectroscopy (Wlodawer et al., J. Mol. Biol. 198 (3), 469-480, 1987; Wagner et al., J. Mol. Biol. 196 (1), 227-231, 1987; Berndt et al., Biochemistry 32 (17), 4564-4570, 1993). [0003]
  • Under the trade name Trasylol®, natural aprotinin was originally employed for the treatment of pancreatitis. Trasylol® is today used in cardiac surgery, since clinical studies have shown that treatment with aprotinin significantly decreases the need for transfusion in operations of this type and leads to the reduction of post-operative bleeding (D. Royston, J. Cardiothorac. Vase. Anesth. 6; 76-100, 1992). [0004]
  • It was possible to show that the replacement of the amino acid in position 15 defining the inhibitory specificity leads to useful aprotinin variants having improved inhibitory properties ([0005] German Patent Specification 3 339 693). Depending on the amino acid introduced, in this way potent inhibitors can be produced which, for example, inhibit the elastase from pancreas or from leucocytes.
  • It was further possible to show that the inhibitory properties of aprotinin and of the variants produced by replacement in position 15 is also determined by further amino acid residues in the contact region between the target protease to be inhibited and the inhibitor molecule. These especially include the additional amino acid residues in positions 14, 16, 17, 18, 19, 34, 38 and 39. Aprotinin variants having improved properties due to replacement of one or more of these amino acid residues in the area of the contact region were described, inter alia, in the following patent applications by way of example: WO 89/01968, WO 89/10374, EP 0 307 592, EP 683 229. [0006]
  • Interestingly, it was possible to improve the pharmacokinetic properties of aprotinin and its variants by amino acid replacements which define the physicochemical properties of the substance. It was thus possible, by lowering the positive net charge of the molecule, significantly to lower the renal binding. Variants of this type were described in the Patent Application WO 92/06111. [0007]
  • For reasons of better industrial preparability, it is convenient in certain cases to carry out a modification to the N-terminal end of the inhibitor molecule. Such modifications can be N-terminal contractions or extensions or deletions of one or more amino acids. N-terminally modified aprotinin variants were described in EP 419 878. [0008]
  • Aprotinin Variants According to the Invention [0009]
  • The aprotinin variants described in the present patent application are distinguished by the following features: [0010]
  • 1. Replacement of one or more amino acids in the active centre of the molecule to improve the activity properties. [0011]
  • 2. Replacement of amino acids to decrease the positive net charge with the aim of improving the immunological and pharmacokinetic properties. [0012]
  • 3. Modification of the N-terminal amino acid sequence for reasons of industrial preparability. [0013]
  • Aprotinin variants which each contain only one of the features mentioned were described in the patent applications cited above. The aprotinin variants according to the invention now combine in their molecular structure two or three of the above-mentioned features. The amino acid sequence is shown by way of example for some variants in the figure. [0014]
  • The aprotinin variants according to the invention are not restricted, however, to the examples named in FIG. 1. The aprotinin variants according to the invention also include variants with the N-terminal extension Ala(2)-Gln(1), with the natural amino acid residue proline in position 2, with the replacement of other amino acids which carry a positive charge by neutral or negatively charged amino acid residues, or with the replacement of other neutral amino acids by negatively charged amino acid residues. The choice of the replacements of amino acid residues here follows the principle of producing a substance which at physiological pH has a reduced positive net charge, preferably in the range from +2 to −2. The changes in the amino acid sequence mentioned, including the N-terminal extension or contractions or deletions can be utilized in any desired combination with one another. The aprotinin variants according to the invention thus include all compounds which contain a combination of the abovementioned features and at physiological pH have a reduced positive net charge. [0015]
  • Surprisingly, it appears that the combination of two or three of the features mentioned not only leads to the obtainment, but in some cases even to the reinforcement of the expression of the individual features. Moreover, it was possible to produce significant new substance properties which are related, for example, to the immunological, the pharmacokinetic and the surface-binding properties. The new variants show a decreased reaction with polyclonal human and rabbit antisera which have been produced using aprotinin. It was further found that the new variants have a distinctly decreased immunogenic behaviour in comparison with aprotinin, i.e. they induce a decreased immune response. It was furthermore possible to show that the variants according to the invention induce a lower release of histamine from blood cells in comparison with aprotinin. The new variants furthermore show a distinctly lower renal accumulation in comparison with aprotinin. The enzyme-kinetic inhibition constants (K[0016] i values) have been surprisingly improved compared with earlier variants of the molecule, in spite of the large number of changes in the body of the molecule.
  • The present invention thus relates to aprotinin variants having a net charge of +3 to −3 at pH 7 and with the amino acids Arg 15 or Arg 15-Ala 17. Preferred variants are those having a net charge of +2 to −2, particularly preferably those having a charge of +1 to −1. [0017]
  • These aprotinin variants are suitable for the inhibition of plasma kallikrein, tissue kallikrein and plasmin. [0018]
  • In addition, these aprotinin variants can have a modified N-terminal sequence. [0019]
  • Thus aprotinin variants with an N-terminal extension or contraction or with deleted amino acids in the N-terminus are intended. [0020]
  • Preferred aprotinin variants are those from the group consisting of DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin, DesPro2-Ser10-Arg15-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin, DesPro2-Ser10-Arg15-Ser17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin, DesPro2-Ser10-Arg15-Ala17-Thr26-Glu31-Asn41-Glu53-aprotinin and DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Asn41-Glu53-aprotinin. [0021]
  • These aprotinin variants can also carry the amino acid proline in position 2. [0022]
  • The invention also relates to medicaments comprising one or more of these aprotinin variants. [0023]
  • The novel proteinase inhibitors described are suitable for the treatment of disease states in which—also as a result of relatively complex surgical methods such as, for example, in cardiac surgery or in alloarthroplastic joint replacement in transplantation medicine—activation of the plasmatic enzyme systems occurs due to extensive or intensive foreign surface contact of the blood. [0024]
  • The inhibitors reduce the blood loss in operations which are associated with an increased risk of bleeding (e.g. heart operations, bone and joint surgery). They are suitable for therapy in the case of shock, polytrauma and cranial and brain trauma, sepsis, disseminated intravasal coagulopathy (DIC), multi-organ failure, inflammatory disorders with involvement of the kallikrein system such as rheumatic joint disorders and asthma. They prevent invasive tumour growth and metastasis by inhibition of plasmin. They are also suitable for pain and oedema therapy due to inhibition of bradykinin synthesis, and for the treatment of strokes. They are also suitable for dialysis therapy and certificial organs to prevent inflammatory disorders, coagulation and increased risk of bleeding. [0025]
  • Preparation of the Aprotinin Variants According to the Invention [0026]
  • To prepare the aprotinin variants according to the invention, it is convenient to employ genetic engineering processes. To do this, using customary molecular biology methods, the genetic engineering information for the synthesis of the aprotinin variants considered in each case is introduced into a suitable microbial expression organism. The recombinant microorganism is fermented; by choice of suitable conditions, the heterologous hereditary information is expressed. The expressed aprotinin variant is subsequently obtained from the culture broth. [0027]
  • Suitable host organisms for the production of the aprotinin variants according to the invention can be bacteria, yeasts or fungi. Expression can be effected intracellularly or, using suitable secretion systems, extracellularly. The aprotinin variants can be correctly processed or fused to peptides or proteins. [0028]
  • Suitable systems for the expression of aprotinin variants have been described in the Patent Applications EP 683 229, WO 89/02463, WO 90/10075 and in various other patent applications of those already mentioned above. [0029]
  • Methods for Carrying out the Invention [0030]
  • Enzymes [0031]
  • The enzymes used (restriction endonucleases, alkaline phosphatases from calf intestine, T4 polynucleotide kinase and T4 DNA ligase) were obtained from Boehringer Mannheim and GIBCO/BRL and employed according to the instructions of the manufacturers. [0032]
  • Molecular Biology Techniques [0033]
  • Routine cloning tasks, such as, for example, the isolation of plasmid DNA from [0034] E. coli (so-called miniprep) and the transformation of E. coli with plasmid DNA were carried out according to Sambrook et al. (Molecular Cloning Cold Spring Harbor, 1989). The host organism employed for transformations was the E. coli strain DH5α (GIBCO/BRL). To isolate larger amounts of plasmid DNA, Qiagen tips (Qiagen) were used. The extraction of DNA fragments from agarose gels was carried out with the aid of Jetsorb according to the details of the manufacturer (Genomed).
  • Oligonucleotides for “site-directed mutagenesis” experiments and primers for PCR and sequencing reactions were prepared using the “380 A DNA synthesizer” from Applied Biosystems. The mutagenesis experiments were carried out according to a process of Deng and Nickoloff (Deng et al., Anal. Biochem. 200, 81-88, 1992) using a kit from Pharmacia Biotech (“Unique Site Elimination Mutagenesis”). All vector constructs and mutagenesis experiments were confirmed by Taq cycle DNA sequencing using fluorescence-labelled terminators on an “ABI 373 A sequencer” (Applied Biosystems). [0035]
  • Transformation of [0036] Saccharomyces cerevisiae
  • Yeast cells, e.g. the strain JC34. 4D (MATα, ura3-52, suc2), were cultured in 10 ml of YEPD (2% glucose; 2% peptone; 1% Difco yeast extract) and harvested at an O.D.[0037] 600 nm of 0.16 to 0.8. The cells were washed with 5 ml of solution A (1 M sorbitol; 10 mM bicine pH 8.35; 3% ethylene glycol), resuspended in 0.2 ml of solution A and stored at −70° C.
  • Plasmid DNA (5 μg) and carrier DNA (50 μg from herring sperm) were added to the frozen cells. The cells were then thawed by shaking for 5 min at 37° C. After addition of 1.5 ml of solution B (40% PEG 1000, 200 mM bicine pH 8.35), the cells were incubated at 30° C. for 60 min, washed with 1.5 ml of solution C (0.15M NaCl; 10 mM bicine pH 8.35) and resuspended in 100 μl. Plating-out was carried out on a selective medium with 2% agar. Transformants were obtained after an incubation of 3 days at 30° C. [0038]
  • Nutrient Media for the [0039] Fermentation
    1. SD2 medium:
    Bacto Yeast Nitrogen Base 6.7 g/l
    Glucose* 20 g/l
    KH2PO4 6.7 g/l
    pH 6.0
    2. SC5 medium:
    Glucose* 20 g/l
    Difco yeast extract 20 g/l
    KH2PO4 6.7 g/l
    (NH4)2SO4 2.0 g/l
    MgSO4 × 7 H2O 1.0 g/l
    Trace element solution SL4 1.0 ml/l
    pH 6.0
    Trace element solution SL4:
    Titriplex III 5 g/l
    FeSO4 × 7 H2O 2 g/l
    ZnSO4 × 7 H2O 0.1 g/l
    MnCl2 × 4 H2O 0.03 g/l
    H3BO3 0.3 g/l
    CoCl2 × 6 H2O 0.2 g/l
    CuCl2 × 2 H2O 0.01 g/l
    NiCl2 × 6 H2O 0.02 g/l
    Na2MoO4 × 2 H2O 0.03 g/l
    3. Fermenter medium:
    Glucose* 2.0 g/l
    Soya peptone 25.0 g/l
    KH2PO4 1.4 g/l
    MgSO4 × 7 H2O 1.0 g/l
    Thiamine chloride 5.1 mg/l
    Inositol 20 mg/l
    Trace element solution 3 ml/l
    Vitamin solution
    3 ml/l
    (NH4)2SO4 3.8 g/l
    pH 5.5
    Feed solution:
    Glucose* 530 g/l
    (NH4)2SO4 5.0 g/l
    KH2PO4 2.9 g/l
    MgSO4 × 7 H2O 3.8 g/l
    Thiamine chloride 13 mg/l
    Inositol 70 mg/l
    Trace element solution 6.8 ml/l
    Vitamin solution 6.8 ml/l
    Trace element solution:
    FeCl3 × 6 H2O 13.5 g/l
    ZnCl2 × 4 H2O 2.0 g/l
    H3BO3 0.5 g/l
    CoCl2 × 6 H2O 2.0 g/l
    CuSO4 × 5 H2O 1.9 g/l
    Na2MoO4 × 2 H2O 2.0 g/l
    CaCl2 × 2 H2O 1.0 g/l
    HCl conc. 100 ml/l
    Vitamin solution:
    Riboflavin 0.42 g/l
    Ca pantothenate 5.9 g/l
    Nicotinic acid 6.1 g/l
    Pyridoxine hydrochloride 1.7 g/l
    Biotin 0.06 g/l
    Folic acid 0.04 g/l
  • Preparation of Working Preserves [0040]
  • Using a stock preserve, 200 ml of SD2 medium in a 1 l Erlenmeyer flask were inoculated to a concentration of 1%. The culture was incubated for 72 hours at 28° C. on the shaker (260 rpm). 2 ml each were then filled into preserve containers and frozen in liquid nitrogen. [0041]
  • Fermentation in the Shaker Flask [0042]
  • As a preculture, 200 ml of SD2 medium were inoculated to 1% with a working preserve in a 1 l flask and fermented for 72 hours at 28° C. on the shaker (260 rpm). Using the preculture, main cultures (200 ml of SC5 medium in 1 l flasks) were inoculated to a concentration of 1% and incubated for 72-96 hours on the shaker at 28° C. [0043]
  • Fermentation in 10 l Bioreactors [0044]
  • As a preculture, 200 ml of SD2 medium were inoculated in a 1 l flask to a concentration of 1% with a working preserve and fermented for 72 hours at 28° C. on the shaker (260 rpm). The main culture in the 10 l fermenter was carried out as a fed-batch fermentation over the course of 96 hours. The nutrient medium used was fermenter medium and the starting volume was 7 l. The fermenter was inoculated with 200 ml of preculture. [0045]
  • Fermentation Conditions: [0046]
  • Temperature: 28° C. [0047]
  • Rotational speed of stirrer: 500 rpm [0048]
  • Aeration: 10 l/min [0049]
  • pH: 5.5 [0050]
  • Head space pressure: 200 mbar [0051]
  • After a fermentation time of 7 hours, feeding was started. The feed rate was controlled via the respiratory quotient (RQ) (RQ=CO[0052] 2 formed/oxygen consumed). If the RQ climbed to values of >1.15, the feed rate was lowered, if it fell to values of <1.05 the feed rate was increased.
  • At regular intervals, samples were removed from the fermenter and the cell growth was determined by measurement of the optical density at 700 nm. Additionally, the concentration of Bay 19-8757 in the supernatant was determined by activity measurement. [0053]
  • At the end of the fermentation, the pH was lowered to 3.0 by addition of 50% (w/v) citric acid and the fermenter was heated at 70° C. for 10 min. The cells were then separated off by centrifugation at 7,500×g and the supernatant was handed over for protein purification. [0054]
  • Materials for Protein Chemical Analysis [0055]
  • The sequence analyses were carried out using a protein sequencer model 473A from Applied Biosystems (Forster City, USA). The standard sequencing programme was used. The sequencer, the various sequencing programmes and the PTH detection system are described in detail in the operating handbook (User's manual protein sequencing system model 473 A) (1989) Applied Biosystems Forster City, Calif. 94404, USA). [0056]
  • The reagents for the operation of the sequencer and the HPLC column for PTH detection were obtained from Applied Biosystems. [0057]
  • The HPLC analyses were carried out using an HP 1090 HPLC system from Hewlett Packard (D-Waldbronn). An RP-18 HPLC column (250 mm×4.6 mm, 5μ material, 300 Angström pore diameter) from Backerbond (D-Groβ Gerau) was used for the separation. [0058]
  • The capillary electrophoresis Model 270 A-HT was from Applied Biosystems (Forster City, Calif. 94404, USA). As a rule, the samples were injected hydrodynamically over various time intervals. The capillary column used (50 μm×72 cm) was from Applied Biosystems. [0059]
  • The amino acid analyses were carried out with an amino acid analyser LC 3000 from Eppendorf Biotronik (D-Maintal). A slightly modified standard separation programme from Biotronik was used. The separation programme and the function of the analyser are described in detail in the apparatus handbook. [0060]
  • The molecular weights were determined with a MALDI I system from Kratos/Shimadzu (D-Duisburg). The SDS electrophoreses were carried out with an electrophoresis system from Pharmacia (D-Freiburg). [0061]
  • The determination of the kinetic data was carried out with the microtitre plate reader from SLT (D-Crailsheim). The washing of the microtitre plates was carried out with a washing apparatus from Dynatec (D-Denkendorf). [0062]
  • Enzymes and substrates were from Calbiochem (D-Bad Soden). All other chemicals and reagents were from Merck (D-Darmstadt) or Sigma (D-Deisenhofen). 96-well plates were obtained from Greiner. [0063]
  • The polyclonal rabbit anti-aprotinin antibodies were raised in rabbits by immunization with aprotinin. The human polyclonal anti-aprotinin antibodies come from patients who were treated with aprotinin. [0064]
  • Protein Chemical Analysis [0065]
  • N-Terminal Sequence Analysis [0066]
  • 1-3 nmol of protease inhibitor dissolved in water were loaded on a sequencer sheet which was preincubated with Polybrene. The protein was sequenced using the fast normal sequencer cycle. The PTH amino acids were identified by means of online HPLC with the aid of a 50 pmol PTH standard. [0067]
  • Amino Acid Analysis [0068]
  • 200 μg of protein were dissolved in 200 μl of 6N HCl and hydrolysed for 1 h at 166° C. About 1 nmol of the sample was added to the amino acid analyser. The amount of amino acid was determined by means of a 5 nmol standard. [0069]
  • SDS Gel Electrophoresis [0070]
  • The SDS gel electrophoresis was carried out according to the conditions of Laemmli. 10 μg of the protease inhibitor were analysed using a 10-20% strength SDS gel and visualized by means of silver staining (Merril et al.). [0071]
  • U. K. Laemmli, Nature 227, 680-685 (1970). [0072]
  • C. R. Merril, M. L. Dunau, D. Goldmann, Anal. Biochem. 100: 201-207 (1981). [0073]
  • Capillary Electrophoresis [0074]
  • 8 ng of the protease inhibitor were investigated by means of capillary electrophoresis on a glass column (length 72 cm, internal diameter 50 μm). Conditions: current density 90 μA, column temperature 25° C., 100 nM phosphate buffer pH 3.0, detection 210 nm, loading under [0075] pressure 3 sec.
  • Reverse-Phase Chromatography [0076]
  • 5 nmol of the protease inhibitor were chromatographed on a Bakerbond RP-18 HPLC column (5μ material, 4.6 nm×250 mm, 300 Angström pore size). The eluent used was an acetonitrile/TFA gradient. Conditions: flow rate 0.7 ml/min, column temperature 40° C., detection 40° C., solvent A 0.1% TFA, Solvent B 0.1% TFA/60% acetonitrile; gradient: 0 min 0% B, 10 min 0% B, 70 min 100% B, 80 min 0% B. [0077]
  • Molecular Weight Determination [0078]
  • 1 μg of the protease inhibitor was analysed using the MALDI technique. The matrix used was sinapic acid. The standard proteins for mass calibration were bovine insulin, cytochrome C and melittin. [0079]
  • Protein Content [0080]
  • The protein content is determined according to the BCA method. In this method, Cu[0081] 2+ ions are reacted by means of the proteins present to give Cu1+ ions which form a complex with bicinchoninic acid, which absorbs at 560 nm.
  • The lyophilized protein is brought to equilibrium moisture content and dissolved in 0.9% NaCl solution at a concentration of 1 mg/ml. A dilution series is prepared. 1000 μl of BCA test reagent (Pierce) are added to 50 μl of sample solution, and the test tube is firmly closed with a stopper and incubated at 60° C. for exactly 30 minutes. After cooling the samples in an ice bath for 5 minutes, measurement is carried out at a temperature of 25° C. and a wavelength of 560 nm. [0082]
  • Activity: (Trypsin Inhibition Test, Titrimetric) [0083]
  • The activity is determined according to a modified F.I.P. trypsin inhibition test. Bay y 19-8757 inhibits the trypsin-catalysed hydrolysis of Nα-benzoyl-L-arginine ethyl ester (BAEE). The carboxyl groups liberated in the reaction are determined by the alkali titration. The trypsin residual activity is a measure of the inhibitory activity of the active compound. [0084]
  • The lyophilized protein is brought to equilibrium moisture content, dissolved in 0.9% NaCl solution at a concentration of 1 mg/ml and a dilution series is prepared. 2 ml of buffer (15 mM borate buffer, pH 8.0 containing 200 mM CaCi[0085] 2) and 0.8 ml of trypsin solution (2 mg/ml) are added to 1 ml of sample solution and the mixture is incubated at 25° C. for 5 minutes. 0.2 ml of BAEE solution (6.8 mg/ml) is then added and the KOH consumption is measured over the course of 5 minutes.
  • Determination of the Cross-Reaction of the Protease Inhibitors with Polyclonal Rabbit or Human Anti-Aprotinin Antibodies [0086]
  • 0.5-10 ng of protease inhibitor or aprotinin dissolved in coupling buffer were bound overnight at 4° C. to a microtitre plate. The wells were washed 4 times with 200 μl of wash buffer each time and 100 μl of the blocking solution were then added. The plate was covered and incubated at 37° C. for one hour. After washing as described above, the polyclonal rabbit anti-aprotinin antibodies (0.2 μg/ml in 1% BSA in PBS buffer) or the polyclonal human antibodies (20 μg/ml in 1% HSA in PBS buffer) were added. The plate was covered and incubated at 37° C. for one hour and then washed as described above. 100 μl of biotinylated anti-rabbit or anti-human antibody (25 μl+10 ml of 1% BSA or 1% HSA in PBS buffer) were then added and the mixture was incubated at 37° C. for one hour. The plate was washed as described above and 100 μl of streptavidin-peroxidase complex (50 μl+10 ml of 1% BSA or 1% HSA in PBS buffer) were then added to each well. The plate was covered and incubated at 37° C. for one hour and then washed as described above. [0087]
  • The substrate reaction was carried out with TMB substrate+peroxidase solution (1+1; 100 μl per well). The reaction was stopped after 10 min using 100 μl/well of 2 M phosphoric acid and the absorption was measured at 450 nm (reference 570 nm). [0088]
    Solutions:
    1. Incubation buffer: 15 nM Na2CO3, 35 mM NaHCO3, pH 9.6
    2. Sample buffers: The samples were dissolved in the incubation buffer
    at a suitable concentration.
    3. Wash solution: 0.1% (v/v) Tween 20 in PBS
    4. Blocking buffer: 3% (w/v) BSA or HSA in PBS.
    • EXAMPLES Example 1
  • Preparation of a Yeast Expression Vector for the Secretion of Recombinant DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin [0089]
  • The starting material used for the preparation of the DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin gene was a DesPro2-Arg15-Ala17 gene, which was cloned into the vector pUC 18 by means of the restriction enzymes HindIII and BamHI. The resulting vector (pEM6.6.L) was subjected to a double strand mutagenesis reaction according to the U.S.E. process (Pharmacia Biotech) with the mutagenesis primer A and the Scal/Mlul U.S.E. selection primer. The mutagenesis primer A had the following sequence: [0090]
  • Primer A [0091]
  • 5 ′[0092] GGCTGCAGAGCTAACCGTAACAACTTCAAATCCGCGGAAGACTGCATGGAAACTTGCGGTGGTGCTTAG 3′. This primer generates the mutations Asn41 and Glu53 in the DesPro2-Arg15-Ala17 aprotinin gene. The analysis of the clones was carried out by means of a restriction digestion using the enzymes ScaI and SphI. The desired sequence was additionally confirmed by DNA sequencing of the clone pEM31.8.L. The further replacements in the 5′ area of the gene (Ser10-Asp24-Thr26-Glu31) were produced with the aid of the PCR technique using the primer B and the ‘reverse 24-mer M13’ primer starting from pEM31.8.L plasmid DNA. The primer B had the following sequence:
  • Primer B [0093]
  • [0094] TGCCTCGAGCCGCCGTCTACTGGGCCCTGCAGAGCTATCATCCGTTACTTCTACGATGCAACTGCAGGCCTGTGTGAAACCTTCGTATACGGC 3′. The Xhol recognition sequence is underlined.
  • The PCR mixture contained 20 ng of pEM31.8.L plasmid DNA, 20 μmol of ‘reverse 24-mer M13’ primer, 60 pmol of primer B, 200 μM of dNTPs, 1×PCR reaction buffer II (Perkin Elmer), 4 mM MgCl[0095] 2 and 2.5 U of Taq DNA polymerase (Perkin Elmer) in a total volume of 100 μl. The ‘cycle’ conditions were: 3 min at 94° C., 30 cycles of, in each case, 1 min at 94° C., 1 min at 55° C. and 1 min at 72° C. and a subsequent 5 min incubation at 72° C. The PCR mixture was diluted 1:5 and ligated with the vector pCRII (Invitrogen). Using the ligation mixture, E. coli DH5α cells were transformed. Positive clones were identified after a restriction digestion with the enzymes XhoI and BamHI and several clones were sequenced. The clone pES9.10.L contained the desired sequence and was employed for the further studies.
  • An [0096] E. coli/yeast shuttle vector (e.g. pA202) was used for the construction of a yeast secretion vector in which the DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin sequence is linked to the yeast alpha-factor pre-pro sequence.
  • The vector pA202 carries an ampicillin resistance gene (bla) and a URA3 gene as selectable marker genes for [0097] E. coli and yeast. Further essential elements of the vector are the Co1 E1 and the 2μ origin of replication (ori). The REP3 locus is also situated in this region. A 1200 bp EcoRI HindIII fragment carries the MFα1 promoter and the N-terminal pre-pro sequence of the yeast alpha-factor precursor protein (Kurjan and Herskowitz, Cell 30, 933 943, 1982). By introduction of a modified DesPro2-Arg15-aprotinin cDNA as a HindIII-BamHI fragment, the recognition sites for the KexII protease (‘Lys-Arg’) within the alpha-factor pre-pro sequence was again prepared (EP 0 419 878).
  • At the 3α end of the DesPro2-Arg15-aprotinin sequence, the vector carries a BamHI-saII fragment of the yeast URA3 gene, which functions in this position as a termination signal for transcription (Yarger et al., Mol. Cell. Biol. 6, 1095-1101, 1986). [0098]
  • A 180 bp DNA fragment was excised from the vector pES9.10.L with Xhol and BamHI, purified by means of agarose gel electrophoresis and cloned into the vector pA202 which was also cleaved with Xhol and BamHI and dephosphorylated. By means of this cloning, the DesPro2-Arg15-aprotinin in the vector pA202 is replaced by the DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin. Yeast cells (JC34.4D) were cloned using the vector pES13.10.L resulting from this cloning. [0099]
  • Other [0100] E. coli/yeast shuttle vectors with different promoters, such as, for example, the constitutive GAPDH or the inducible GAL 10 promoter, can be prepared in a similar manner and also lead to the secretion of DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin.
  • In addition, it is of course also possible to employ shuttle vectors with other yeast replication origins, such as, for example, the segment (ars) which autonomically replicates chromosomally. [0101]
  • Besides the URA3 gene, suitable selectable marker genes are those genes which help an auxotrophic yeast mutant to prototrophy, such as, for example, the LEU2, HIS3 or TRP1 genes. Additionally, genes can of course also be employed whose products impart resistance to various antibiotics, such as, for example, the aminoglycoside G418. [0102]
  • Other yeasts, such as, for example, the methylotrophic yeasts [0103] Pichia pastoris or Hansenula polymorpha, are also able, after transformation with suitable vectors, to produce DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin.
    • Example 2
  • Preparation of a Yeast Expression Vector for the Secretion of Recombinant Ser10 -Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin with the Natural N-Terminal Sequence ‘Arg-Pro-Asp’[0104]
  • For the preparation of a yeast expression vector which allows the secretion of Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin with the natural N-terminal sequence ‘Arg-Pro-Asp’, the MFα1 promoter with the α-factor pre-sequence and the 5′ end of the aprotinin gene (up to the recognition sequence of the restriction enzyme Xho1) was first amplified by means of PCR and cloned. The primers used had the following sequence: [0105]
  • Primer C: [0106]
  • 5′[0107] GGGATATCTATTGATAAGATTTAAAGGTATTTGACAAG 3′.
  • The EcoRV recognition sequence is underlined. [0108]
  • Primer D: [0109]
  • 5′[0110] GGGCTCGAGGCAGAAATCTGGTCTAGCCAAAGCAGAAGAAGCAGCGAACAAGACAGCAGTGAAAATAGATGGAATCTCATTCTTTTAATCGTTTATATT 3′.
  • The Xho1 recognition sequence is underlined. [0111]
  • The PCR mixture contained 200 ng of pA202 plasmid DNA, 0.2 μM primer C, 0.2 μM primer D, 200 μM dNTPs, 1×PCR reaction buffer 11 (Stratagene, Opti-Prime™) and 2.5 U of Taq DNA polymerase (Perkin Elmer) in a total volume of 50 μl. The ‘cycle’ conditions were: 1 min at 94° C., 30 cycles with, in each case, 1 min at 94° C., 1 min at 50° C. and 2 min at 72° C. and a subsequent 5 min incubation at 72° C. The PCR mixture was diluted 1:5 and ligated with the vector pCRII (Invitrogen). Using the ligation mixture, [0112] E. coli DH5α cells were transformed. Positive clones were identified after a restriction digestion with the enzyme EcoRI and several clones were sequenced. The clone pIU20.11.L was employed for the further studies.
  • The [0113] E. coli/yeast shuttle vector pYES2 (Invitrogen) was used for the construction of a yeast secretion vector in which the Ser10-Arg15-Ala17-Asp24-Thr26-Glu311-Asn41-Glu53-aprotinin sequence is linked directly to the yeast alpha-factor pre-sequence. The vector pYES2 was first cleaved with the restriction enzymes SspI and BamHI, dephosphorylated and gel-purified. The GAL1 promoter present on the vector pYES2 and the f1 ori are removed in this way. An about 1030 bp DNA fragment was excised with EcoRV and Xho1 from the vector pIU20.11.L, purified by means of agarose gel electrophoresis and cloned together with an about 180 bp Xho1 and BamHI fragment from the vector pES9.10.L into the vector pYES2 cleaved with SspI and BamHI. Using the ligation mixture, E. coli DH5α cells were transformed. Positive clones were identified and sequenced after a restriction digestion with the enzyme Xho1. Yeast cells (JC34.4D) were transformed using the vector pIU28.11.L resulting from this cloning. The expression vector pIU28.11.L no longer contains an α-factor pro-sequence, so that the processing of the Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin takes place exclusively by means of the signal peptidase and is independent of the cleavage by the KexII protease.
    • Example 3
  • Fermentation of [0114] Saccharomyces cerevisiae
  • A [0115] Saccharomyces cerevisiae expression strain was fermented as described above.
    • Example 4
  • Purification of Aprotinin Derivatives Without Net Charge at Neutral pH [0116]
  • 1. Survey of Suitable Purification Processes [0117]
  • After the fermentation, the cells are separated off by centrifugation and the supernatant which remains is filtered in order to remove remaining cells. [0118]
  • The cell-free supernatant is adjusted to [0119] pH 3 by addition of concentrated citric acid. The solution must be suitably diluted with purified water in order to establish a conductivity of less than 8 mS/cm. Subsequently, the solution is applied to a cation exchanger column, which has previously been equilibrated with an acid buffer. Unbound material is removed by copious washing with starting buffer. The product is eluted with the aid of a salt gradient. The fractions obtained are investigated further for their product content with the aid of reverse-phase high-pressure liquid chromatography (RP-HPLC) and a biological activity test which determines the protease inhibition. Fractions which contain the product are combined and applied directly to a preparative RP-HPLC column. The column was previously equilibrated with an acidic buffer. Unbound protein is removed by washing the column with starting buffer. The product is eluted with the aid of an organic solvent gradient. The fractions are again investigated further for their product content as already described above and those fractions which contain product are combined. Depending on the purity of the product achieved, it may possibly be necessary to purify the combined fractions on a second RP-HPLC column. The conditions are essentially the same as those already described. The product solution obtained is diluted with water for injection purposes and dispensed in suitable portions and freeze-dried.
  • Other methods for the purification of aprotinin derivatives without net charge at neutral pH which can be combined with the processes described above are affinity chromatography on Sepharose-immobilized trypsin and gel permeation chromatography. [0120]
  • 2. Purification of DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin [0121]
  • Material from 10 l fermentations was purified according to the following process. After the fermentation was complete, the fermenter contents were adjusted to [0122] pH 3 using concentrated citric acid and heated at 70° C. for 10 minutes. The cells were then removed by centrifugation (15 minutes, 7500×g, Heraeus centrifuge) and the supernatant obtained was filtered (8 μm to 0.2 μm, Millipore, Germany). From this stage, the supernatant can be stored until further use by freezing at −18° C. The solution was then diluted to a conductivity of less than 8 mS/cm by addition of purified water and applied to an SP-sepharose FF column (Pharmacia, Sweden). The column had previously been equilibrated with 50 nM citrate-NaOH buffer, pH 3. Unbound protein was removed by intensive washing with the same buffer. The product was then eluted with the aid of a salt gradient (1 M NaCl). The fractions obtained were investigated for their product content with the aid of reverse-phase high-pressure liquid chromatography (RP-HPLC, C4) and by testing of the protease inhibition activity. Those fractions which contain the desired product were combined.
  • The product solution was then applied directly to the first RP-HPLC column (Source 15 RPC, Pharmacia, Sweden), which had previously been equilibrated with 0.1% trifluoroacetic acid/water. Unbound protein was removed by intensive washing with the same buffer. The product was eluted with the aid of a linear acetonitrile gradient (0-70%). The fractions obtained were again investigated for the product content using the methods described above and those which contained product were combined. [0123]
  • For the final purification, the product-containing solution was diluted with water for injection purposes and applied to the second RP-HPLC column (Vydac C8, Vydac, USA), which had previously been equilibrated with 0.1% trifluoroacetic acid/water. Unbound protein was removed by intensive washing with the same buffer. The product was eluted with the aid of a linear acetonitrile gradient (0-70%). The fractions obtained were again investigated for the product content using the methods described above and those which contained product were combined. [0124]
  • The product solution obtained was diluted with water for injection purposes, dispensed in suitable portions (20, 10, 1 and 0.2 mg), lyophilized and analysed. [0125]
    • Example 5
  • Determination of the K[0126] i of Human Plasma Kallikrein Using DesPro-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin
    • Example
  • 1 unit of human plasma kallikrein was diluted to 16 ml with buffer (0.05 M tris/0.1 M NaCl, 0.05% Tween 20; pH 8.2). 200 μl of this enzyme solution were mixed with decreasing volumes of test buffer (250, 240, 230, 220, 200, 180, 170, 150, 100 and 50 μl) and then increasing amounts of inhibitor in the assay buffer were added (10, 20, 30, 50, 70, 80, 100, 150, 200 and 250 μl; concentration 0.7 μg/μl). [0127]
  • The enzyme/inhibitor solution was preincubated at room temperature for 4 hours. 180 μl of each solution was then added to the well of a microtitre plate and mixed with 20 μl of substrate solution. The change in the absorption was measured at 405 nm for 10 min. The rate of the enzyme reactions was determined and the K[0128] i value was calculated from this according to the method of Bieth (Biochemical Medicine 32: 387-97 (1984)).
    Substrate stock solution: 0.1M in DMSO
    Substrate solution: 1 × 10−3M S-2302 in assay buffer
    Assay buffer: 0.05M tris-(hydroxymethyl)-aminomethane,
    0.1M NaCl, 0.05% Tween 20; pH 8.2; 1 ml of
    benzyl alcohol/l.
  • The kinetic constants of the complexation with the enzymes plasmin factor XIa, bovine trypsin and chymotrypsin were determined by the same procedure. The substrates were Chromozym PL for plasmin, HD-Pro-Phe-Arg-pNA for factor XI, S-2444 for trypsin and Suc-Phe-Leu-Phe-pNA for chymotrypsin. [0129]
    • Example 6
  • Results of the Protein Chemical Characterization of DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin [0130]
  • The protease inhibitor DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin was prepared by secretion by means of a yeast organism modified by genetic engineering. It was purified to homogeneity from the yeast supernatant by various chromatographic processes. The identity of the inhibitor with the cloned sequence is shown by the following protein analytical investigations. [0131]
  • N-Terminal Sequence Analysis [0132]
  • The protease inhibitor was completely sequenced over 57 steps. The following list shows the protein sequence determined, which is identical to the cloned sequence. [0133]
    1
    Arg-Asp-Phe-Cys-Leu-Glu-Pro-Pro-Ser-Thr-Gly-Pro-
    Cys-Arg-Ala-Ala-IIe-IIe-Arg-Tyr-
    21
    Phe-Tyr-Asp-Ala-Thr-Ala-Gly-Leu-Cys-Glu-Thr-Phe-
    Val-Tyr-Gly-Gly-Cys-Arg-Ala-
    40
    Asn-Arg-Asn-Asn-Phe-Lys-Ser-Ala-Glu-Asp-Cys-Met-
    Glu-Thr-Cys-Gly-Gly-Ala
  • Sequence Analysis of DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin over 57 Steps. [0134]
  • Amino Acid Analysis [0135]
  • Amino acid analysis is an important quantitative parameter for the characterization of a protein. Besides the protein content, in the case of known primary structure, the number of individual amino acids is determined. The amino acid analysis of DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin is in good agreement with the theoretical values from the primary structure (Tab. 1). [0136]
    TABLE 1
    Amino acid analysis of DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-
    Asn41-Glu53-aprotinin. The number of residues are based on Ala = 7.
    Amino acid Number of residues Theoretical numbers
    CysSO3H 5.28 6
    Asp 6.27 6
    Thr 3.49 4
    Ser 1.58 2
    Glu 4.25 4
    Gly 6.16 6
    Ala 7.00 7
    Val 0.98 1
    Met 1.10 1
    Ile 1.66 2
    Leu 1.89 2
    Tyr 2.49 3
    Phe 4.11 4
    Lys 1.05 1
    Arg 4.73 5
    Pro 3.23 3
  • Reverse-Phase Chromatography [0137]
  • In the HPLC chromatography of proteins on chemically bonded reverse phases, binding to the phase used occurs via a hydrophobic interaction of the proteins. The proteins are displaced by organic solvents (mobile phase) according to the strength of their binding to the stationary phase. For this reason, this method is a good criterion for the assessment of the purity of a protein. DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin elutes as a single peak from the RP-18 phase. It was shown that the isolated protease inhibitor is very clean. [0138]
  • CE Chromatography [0139]
  • Capillary electrophoresis allows the separation of peptides and proteins on the basis of their charge in an electrical field. The quality of the separation in this case depends on the buffer, the pH, the temperature and the additives used. The capillaries employed are so-called “fused silica” columns having an internal diameter of 50-100 μm. DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin was separated on a “fused silica” column in an electrical field. The electropherogram shows a narrow peak. [0140]
  • Molecular Weight Determination [0141]
  • The molecular weight of DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin was determined to be 6223 daltons using the MALDI technique. In this case, the molecular weight determined is in good agreement with the theoretical value of 6215 daltons within the bounds of the accuracy of the measuring method. Sinapic acid was employed as a matrix. [0142]
  • SDS Gel Electrophoresis [0143]
  • DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin was analysed under reducing and non-reducing conditions by means of SDS electrophoresis. It shows a band in the range of about 6.5 kD. [0144]
    • Example 7
  • Determination of the k[0145] i Values for the Complexation of Enzymes with DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin
  • The inhibitory constants of DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin were determined for various enzymes. Table 2 shows the k[0146] i values.
    TABLE 2
    Inhibitory constants of the complexation of DesPro2-Ser10-Arg15-Ala17-
    Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin with the enzymes and plasma
    kallikrein, factor XIa, bovine chymotrypsin and bovine trypsin.
    Enzyme ki [M]
    Plasma kallikrein 2 × 10−11
    Plasmin 5 × 10−10
    Factor XIa 5 × 10−10
    Trypsin 2 × 10−11
    Chymotrypsin 9 × 10−9 
    • Example 8
  • Interaction of the Protease Inhibitors with Polyclonal Rabbit or Human Anti-Aprotinin Antibodies [0147]
  • The protease inhibitors prepared by recombinant methods were investigated further for their cross-reactivity using polyclonal rabbits or human anti-aprotinin antibodies. It was found that the various protease inhibitor variants only show a very weak interaction with the aprotinin antisera. [0148]
                      
    #              SEQUENCE LIS
    #TING
    (1) GENERAL INFORMATION:
       (iii) NUMBER OF SEQUENCES: 5
    (2) INFORMATION FOR SEQ ID NO: 1:
         (i) SEQUENCE CHARACTERISTICS:
              (A) LENGTH: 69 Base 
    #pairs
              (B) TYPE: Nucleic Acid
              (C) STRANDEDNESS: Single
              (D) TOPOLOGY: linear
        (ii) MOLECULE TYPE: DNA (Genomic)
       (iii) HYPOTHETICAL: NO
        (iv) ANTI-SENSE: NO
        (vi) ORIGINAL SOURCE:
              (A) ORGANISM: Primer A
        (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 
    #1:
    GGCTGCAGAG CTAACCGTAA CAACTTCAAA TCCGCGGAAG     
    #                  
    #    40
    ACTGCATGGA AACTTGCGGT GGTGCTTAG         
    #                  
    #            69
    (2) INFORMATION FOR SEQ ID NO: 2:
         (i) SEQUENCE CHARACTERISTICS:
              (A) LENGTH: 96 Base 
    #pairs
              (B) TYPE: Nucleotide
              (C) STRANDEDNESS: Single
              (D) TOPOLOGY: Linear
        (ii) MOLECULE TYPE: Genomic DNA
       (iii) HYPOTHETICAL: NO
        (iv) ANTI-SENSE: NO
         (v) FRAGMENT TYPE: linear
        (vi) ORIGINAL SOURCE:
              (A) ORGANISM: Primer B
        (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 
    #2:
    TGCCTCGAGC CGCCGTCTAC TGGGCCCTGC AGAGCTGCTA     
    #                  
    #    40
    TCATCCGTTA CTTCTACGAT GCAACTGCAG GCCTGTGTGA     
    #                  
    #    80
    AACCTTCGTA TACGGC             
    #                  
    #                  
    #    96
    (2) INFORMATION FOR SEQ ID NO: 3:
         (i) SEQUENCE CHARACTERISTICS:
              (A) LENGTH: 38 Base 
    #pairs
              (B) TYPE: Nucleotide
              (C) STRANDEDNESS: Single
              (D) TOPOLOGY: linear
        (ii) MOLECULE TYPE: Genomic DNA
         (v) FRAGMENT TYPE: linear
        (vi) ORIGINAL SOURCE:
              (A) ORGANISM: Primer C
        (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 
    #3:
    GGGATATCTA TTGATAAGAT TTAAAGGTAT TTGACAAG      
    #                  
    #     38
    (2) INFORMATION FOR SEQ ID NO: 4:
         (i) SEQUENCE CHARACTERISTICS:
              (A) LENGTH: 100 Base 
    #pairs
              (B) TYPE: Nucleotide
              (C) STRANDEDNESS: Single
              (D) TOPOLOGY: linear
        (ii) MOLECULE TYPE: Genomic DNA
       (iii) HYPOTHETICAL: NO
        (iv) ANTI-SENSE: NO
         (v) FRAGMENT TYPE: linear
        (vi) ORIGINAL SOURCE:
              (A) ORGANISM: Primer D
        (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 
    #4:
    GGGCTCGAGG CAGAAATCTG GTCTAGCCAA AGCAGAAGAA     
    #                  
    #    40
    GCAGCGAACA AGACAGCAGT GAAAATAGAT GGGAATCTCA     
    #                  
    #    80
    TTCTTTTAAT CGTTTATATT            
    #                  
    #                  
    #100
    (2) INFORMATION FOR SEQ ID NO: 5:
         (i) SEQUENCE CHARACTERISTICS:
              (A) LENGTH: 57 Amino 
    #acids
              (B) TYPE: Amino acid
              (C) STRANDEDNESS: Single
              (D) TOPOLOGY: linear
        (ii) MOLECULE TYPE: Peptide
         (v) FRAGMENT TYPE: linear
        (vi) ORIGINAL SOURCE:
              (A) ORGANISM: Aprotinin 
    #variant
        (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 
    #5:
    Arg Asp Phe Cys Leu Glu Pro Pro Ser Thr Gl
    #y Pro Cys Arg Ala Ala
    1                5  
    #                 10 
    #                 15
    Ile Ile Arg Tyr Phe Tyr Asp Ala Thr Ala Gl
    #y Leu Cys Glu Thr Phe
                 20     
    #             25     
    #             30
    Val Tyr Gly Gly Cys Arg Ala Asn Arg Asn As
    #n Phe Lys Ser Ala Glu
             35         
    #         40         
    #         45
    Asp Cys Met Glu Thr Cys Gly Gly Ala
        50              
    #    55

Claims (6)

1. Aprotinin variants having a net charge of +3 to −3 at pH 7 and with the amino acids Arg15 or Arg15-Ala17 in the binding region.
2. Aprotinin variants according to claim 1 for the inhibition of serine proteases.
3. Aprotinin variants according to claim 1 having a modified N-terminal sequence.
4. Aprotinin variants according to claim 1 having an N-terminal extension or contraction or having deleted amino acids in the N-terminus.
5. Aprotinin variants from the group consisting of DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin, DesPro2-Ser10-Arg15-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin, DesPro2-Ser10-Arg15-Ser17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin, DesPro2-Ser10-Arg15-Ala17-Thr26-Glu31-Asn41-Glu53-aprotinin, DesPro2-Ser10-Arg15-Ala17-Asp24-Thr26-Asn41-Glu53-aprotinin, Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin, Ser10-Arg15-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin, Ser10-Arg15-Ser17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin, Ser10-Arg15-Ala17-Thr26-Glu31-Asn41-Glu53-aprotinin and Ser10-Arg15-Ala17-Asp24-Thr26-Asn41-Glu53-aprotinin.
6. Medicaments comprising one or more of the aprotinin variants according to claim 1.
US10/252,967 1996-07-25 2002-09-23 Aprotinin variants having improved properties Abandoned US20030096752A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/252,967 US20030096752A1 (en) 1996-07-25 2002-09-23 Aprotinin variants having improved properties

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19629982A DE19629982A1 (en) 1996-07-25 1996-07-25 Aprotinin variants with improved properties
DE19629982.9 1996-07-25
US08/896,322 US6482798B2 (en) 1996-07-25 1997-07-17 Aprotinin variants having improved properties
US10/252,967 US20030096752A1 (en) 1996-07-25 2002-09-23 Aprotinin variants having improved properties

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/896,322 Division US6482798B2 (en) 1996-07-25 1997-07-17 Aprotinin variants having improved properties

Publications (1)

Publication Number Publication Date
US20030096752A1 true US20030096752A1 (en) 2003-05-22

Family

ID=7800774

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/896,322 Expired - Fee Related US6482798B2 (en) 1996-07-25 1997-07-17 Aprotinin variants having improved properties
US10/252,967 Abandoned US20030096752A1 (en) 1996-07-25 2002-09-23 Aprotinin variants having improved properties

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/896,322 Expired - Fee Related US6482798B2 (en) 1996-07-25 1997-07-17 Aprotinin variants having improved properties

Country Status (37)

Country Link
US (2) US6482798B2 (en)
EP (1) EP0821007B1 (en)
JP (1) JPH10101700A (en)
KR (1) KR980009283A (en)
CN (1) CN1172116A (en)
AR (1) AR008783A1 (en)
AT (1) ATE260975T1 (en)
AU (2) AU2870197A (en)
BG (1) BG101787A (en)
BR (1) BR9704068A (en)
CA (1) CA2207071A1 (en)
CO (1) CO4890857A1 (en)
CZ (1) CZ236797A3 (en)
DE (2) DE19629982A1 (en)
DZ (1) DZ2276A1 (en)
EE (1) EE9700177A (en)
ES (1) ES2217350T3 (en)
HN (1) HN1997000094A (en)
HR (1) HRP970384A2 (en)
HU (1) HUP9701290A3 (en)
ID (1) ID17508A (en)
IL (1) IL121361A0 (en)
MA (1) MA24279A1 (en)
NO (1) NO973426L (en)
NZ (1) NZ328402A (en)
PE (1) PE92298A1 (en)
PL (1) PL321341A1 (en)
RU (1) RU2197983C2 (en)
SG (1) SG71714A1 (en)
SK (1) SK101997A3 (en)
SV (1) SV1997000068A (en)
TN (1) TNSN97130A1 (en)
TR (1) TR199700688A2 (en)
TW (1) TW480271B (en)
UA (1) UA55380C2 (en)
YU (1) YU31697A (en)
ZA (1) ZA976585B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD534019S1 (en) * 2005-02-18 2006-12-26 Atico International Usa, Inc. Portion of an anti-pinching device of a folding chair in a stowed position

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19725014A1 (en) * 1997-06-13 1998-12-17 Bayer Ag Aprotinin variants with improved properties and bikunins of aprotinin variants
US6974188B2 (en) * 2003-08-13 2005-12-13 Cosco Management, Inc. Chair with pivotable chair back
WO2006042327A2 (en) * 2004-10-12 2006-04-20 Large Scale Biology Corporation Plant-produced recombinant aprotinin and aprotinin variants
US20060218667A1 (en) * 2004-10-12 2006-09-28 Vojdani Fakhrieh S Plant-produced recombinant aprotinin and aprotinin variants
JP5175108B2 (en) * 2005-02-18 2013-04-03 アンジオケム・インコーポレーテッド Aprotinin polypeptides for transporting compounds across the blood brain barrier
WO2008077478A1 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
WO2008110301A1 (en) * 2007-03-13 2008-09-18 Bayer Schering Pharma Aktiengesellschaft Aprotinin variants with improved properties
DE102007056231A1 (en) 2007-09-08 2009-03-12 Bayer Healthcare Ag Proteins comprising a Kunitz domain useful as protease inhibitors for therapeutic purposes
BRPI1103921A2 (en) 2011-08-17 2013-08-06 Mahle Metal Leve Sa cast iron cylinder and alloy liner
KR20240130132A (en) * 2022-01-05 2024-08-28 헬릭스 나노테크놀로지스 인코포레이티드 Composition comprising alpha-factor prepro sequence and use thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595674A (en) * 1983-07-28 1986-06-17 Bayer Aktiengesellschaft Homologues of aprotinin with, in place of lysine, other aminoacids in position 15, process for their preparation and their use as medicaments
US4595974A (en) * 1984-09-10 1986-06-17 Burroughs Corporation Base drive circuit for a switching power transistor
US5118668A (en) * 1987-08-07 1992-06-02 Bayer Aktiengesellschaft Variants of bovine pancreatic trypsin inhibitor and pharmaceutical use thereof
US5164482A (en) * 1989-09-13 1992-11-17 Bayer Aktiengesellschaft Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof
US5231010A (en) * 1989-09-13 1993-07-27 Bayer Aktiengesellschaft Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof
US5591603A (en) * 1987-08-28 1997-01-07 Novo Nordisk A/S Process for preparing aprotinin and aprotinin analogs in yeast cells
US5747449A (en) * 1992-07-13 1998-05-05 Corvas International, Inc. Bovine pancreatic trypsin inhibitor derived inhibitors of factor XA

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK225488D0 (en) * 1988-04-26 1988-04-26 Novo Industri As POLYPEPTIDE
DK463887D0 (en) 1987-09-07 1987-09-07 Novo Industri As GAERLEADER
DK105489D0 (en) 1989-03-03 1989-03-03 Novo Nordisk As POLYPEPTIDE
IL99585A0 (en) * 1990-10-01 1992-08-18 Novo Nordisk As Aprotinin analogues,their production and pharmaceutical compositions containing them
KR100199565B1 (en) * 1994-08-19 1999-06-15 차동천 Method for manufacturing interlayer of sublimation thermal transfer recording paper

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595674A (en) * 1983-07-28 1986-06-17 Bayer Aktiengesellschaft Homologues of aprotinin with, in place of lysine, other aminoacids in position 15, process for their preparation and their use as medicaments
US4595974A (en) * 1984-09-10 1986-06-17 Burroughs Corporation Base drive circuit for a switching power transistor
US5118668A (en) * 1987-08-07 1992-06-02 Bayer Aktiengesellschaft Variants of bovine pancreatic trypsin inhibitor and pharmaceutical use thereof
US5591603A (en) * 1987-08-28 1997-01-07 Novo Nordisk A/S Process for preparing aprotinin and aprotinin analogs in yeast cells
US5621074A (en) * 1987-08-28 1997-04-15 Novo Nordisk A/S Aprotinin analogs
US5164482A (en) * 1989-09-13 1992-11-17 Bayer Aktiengesellschaft Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof
US5231010A (en) * 1989-09-13 1993-07-27 Bayer Aktiengesellschaft Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof
US5747449A (en) * 1992-07-13 1998-05-05 Corvas International, Inc. Bovine pancreatic trypsin inhibitor derived inhibitors of factor XA

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD534019S1 (en) * 2005-02-18 2006-12-26 Atico International Usa, Inc. Portion of an anti-pinching device of a folding chair in a stowed position

Also Published As

Publication number Publication date
HUP9701290A2 (en) 1999-06-28
HU9701290D0 (en) 1997-09-29
DE59711356D1 (en) 2004-04-08
MX9705605A (en) 1998-08-30
EP0821007A3 (en) 1998-11-18
BR9704068A (en) 1999-01-05
KR980009283A (en) 1998-04-30
NO973426D0 (en) 1997-07-24
NO973426L (en) 1998-01-26
PE92298A1 (en) 1999-02-13
ZA976585B (en) 1998-02-03
PL321341A1 (en) 1998-02-02
RU2197983C2 (en) 2003-02-10
MA24279A1 (en) 1998-04-01
HRP970384A2 (en) 1998-04-30
NZ328402A (en) 1999-03-29
IL121361A0 (en) 1998-01-04
ATE260975T1 (en) 2004-03-15
EE9700177A (en) 1998-02-16
SG71714A1 (en) 2000-04-18
AR008783A1 (en) 2000-02-23
BG101787A (en) 1998-10-30
DE19629982A1 (en) 1998-01-29
HN1997000094A (en) 1997-12-26
HUP9701290A3 (en) 2000-08-28
US6482798B2 (en) 2002-11-19
ID17508A (en) 1998-01-08
TNSN97130A1 (en) 2005-03-15
CN1172116A (en) 1998-02-04
TR199700688A2 (en) 1998-02-21
YU31697A (en) 1999-07-28
CZ236797A3 (en) 1998-02-18
CO4890857A1 (en) 2000-02-28
SV1997000068A (en) 1998-07-09
AU762041B2 (en) 2003-06-19
US20020103334A1 (en) 2002-08-01
UA55380C2 (en) 2003-04-15
AU5178701A (en) 2001-09-06
ES2217350T3 (en) 2004-11-01
EP0821007A2 (en) 1998-01-28
EP0821007B1 (en) 2004-03-03
TW480271B (en) 2002-03-21
AU2870197A (en) 1998-02-05
SK101997A3 (en) 1998-03-04
JPH10101700A (en) 1998-04-21
DZ2276A1 (en) 2002-12-18
CA2207071A1 (en) 1998-01-25

Similar Documents

Publication Publication Date Title
JP3345420B2 (en) Novel human kunitz protease inhibitors and variants thereof
EP0339942A2 (en) Aprotinin analogues and process for the production thereof
EP0621869B1 (en) Human kunitz-type protease inhibitor variants
EP0402068B1 (en) Polypeptides and polypeptide analogues with inhibitory activity against human elastase
CA2127249A1 (en) A human kunitz-type protease inhibitor variant
US6482798B2 (en) Aprotinin variants having improved properties
US5378614A (en) Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
KR0169976B1 (en) Recombinant aprotinin variants, genetically engineered process for the microbial preparatin of homogeneously processed aprotinin variants and therapeutic use thereof
Pohlig et al. Purification, Characterization and Biological Evaluation of Recombinant Leech‐Derived Tryptase Inhibitor (rLDTI) Expressed at High Level in the Yeast Saccharomyces Cerevisiae
US5707831A (en) Process for preparing recombinant aprotinin and recombinant aprotinin variants having the natural N-terminal sequence
JP2002503958A (en) Aprotinin variants and aprotinin variants bikunin with improved properties
MXPA97005605A (en) Aprotinin variants with improved properties
HK1008224A (en) Aprotinin variants having improved properties

Legal Events

Date Code Title Description
AS Assignment

Owner name: SCHRODER, WERNER, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER AKTIENGESELLSCHAFT;REEL/FRAME:014268/0306

Effective date: 20031202

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION